A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
Status:
Recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients
with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type